KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(... ( KV acknowledges validity of Purdue ...)

KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute

Date:6/9/2009

KV acknowledges validity of Purdue patents; Receives limited license rights to all strengths of oxycodone controlled-release tablets

ST. LOUIS, June 9 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa; KVb) of St. Louis, MO., today announced it has entered into a settlement agreement with Purdue Pharma L.P. of Stamford, Conn., in regard to the patent infringement lawsuit between the two companies. Under the terms of the settlement agreement, KV Pharmaceutical Company acknowledges that Purdue Pharma's OxyContin(R) patents are valid and enforceable and infringed. In exchange, Purdue will grant KV Pharmaceutical Company certain limited non-exclusive, royalty-bearing, non-transferable rights to sell in the United States generic versions of the drug OxyContin(R) (oxycodone HCl controlled-release) for a limited period of time. The Companies have agreed to continue to discuss the final location for the manufacturing of this product.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a subsidiary that competes with branded products, and Ther-Rx Corporation, the company's branded drug subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate Web site at www.kvpharmaceutical.com.

About Purdue Pharma L.P.

Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering res
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
2. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
3. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
4. Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)
5. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
6. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
7. Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference
8. Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 2009
10. Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications
11. Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering

Post Your Comments:

KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(...( KV acknowledges validity of Purdue ...),Health